Method for producing insulin-producing cells

Patent metadata

Field	Value
Publication number	US-12018283-B2
Application number	US-201916962190-A
Country	US
Kind code	B2
Filing date	Jan 24, 2019
Priority date	Jan 30, 2018
Publication date	Jun 25, 2024
Grant date	Jun 25, 2024

Abstract

The present invention chiefly aims to provide a process for directly inducing insulin-producing cells from somatic cells without performing artificial gene transfer. The present invention can include a process for producing an insulin-producing cell by inducing differentiation directly from a somatic cell, the process comprising a step of culturing the somatic cell in the presence of a cAMP inducer, and six members selected from the group consisting of a GSK3 inhibitor, a TGF-β inhibitor, a BMP inhibitor, a p53 inhibitor, a PI3K inhibitor, a Notch inhibitor and a RAR agonist, or all members thereof. The insulin-producing cells obtained by the present invention are useful in regenerative medicine and the like.

First claim

The invention claimed is:

1. A process for producing an insulin-producing cell by inducing differentiation directly from a fibroblast without performing artificial gene transfer, the process comprising culturing the fibroblast in the presence of:
0.2 μmol/L to 50 μmol/L of at least one cAMP inducer;
0.1 μmol/L to 20 μmol/L of at least one PI3K inhibitor; and
five or all six members selected from the group consisting of
0.1 μmol/L to 20 μmol/L of at least one GSK3 inhibitor,
0.1 μmol/L to 30 μmol/L of at least one TGF-β inhibitor,
0.1 μmol/L to 10 μmol/L of at least one BMP inhibitor,
0.5 μmol/L to 30 μmol/L of at least one p53 inhibitor,
0.2 μmol/L to 30 μmol/L of at least one Notch inhibitor and
0.05 μmol/L to 10 μmol/L of at least one RAR agonist,

wherein the GSK3 inhibitor comprises CHIR99021, the TGF-β inhibitor comprises SB431542, the p53 inhibitor comprises pifithrin, the PI3K inhibitor comprises LY294002, the Notch inhibitor comprises DAPT, the RAR agonist comprises retinoic acid or the cAMP inducer comprises forskolin.

2. The process for producing an insulin-producing cell according to claim 1 , wherein the culturing comprises culturing the fibroblast in the presence of the GSK3 inhibitor, the TGF-β inhibitor, the p53 inhibitor, the Notch inhibitor, the RAR agonist, the PI3K inhibitor, and the cAMP inducer.

3. The process for producing an insulin-producing cell according to claim 1 , wherein the fibroblast is cultured in the presence of the BMP inhibitor, and the BMP inhibitor comprises LDN193189.

4. The process for producing an insulin-producing cell according to claim 1 , wherein the fibroblast is cultured in the presence of the GSK3 inhibitor, and the GSK3 inhibitor comprises CHIR99021.

5. A process for producing an insulin-producing cell by inducing differentiation directly from a fibroblast without performing artificial gene transfer, the process comprising culturing the fibroblast in the presence of
0.1 μmol/L to 20 μmol/L of at least one GSK3 inhibitor,
0.1 μmol/L to 30 μmol/L of at least one TGF-β inhibitor,
0.1 μmol/L to 20 μmol/L of at least one PI3K inhibitor,
0.2 μmol/L to 30 μmol/L of at least one Notch inhibitor, and
0.2 μmol/L to 50 μmol/L of at least one cAMP inducer,
wherein the GSK3 inhibitor comprises CHIR99021, the TGF-β inhibitor comprises SB431542, the PI3K inhibitor comprises LY294002, the Notch inhibitor comprises DAPT, or the cAMP inducer comprises forskolin.

6. A composition for producing an insulin-producing cell by inducing differentiation directly from a fibroblast without performing artificial gene transfer, the composition comprising:
0.2 μmol/L to 50 μmol/L of at least one cAMP inducer;
0.1 μmol/L to 20 μmol/L of at least one PI3K inhibitor; and
five or all six members selected from the group consisting of
0.1 μmol/L to 20 μmol/L of at least one GSK3 inhibitor,
0.1 μmol/L to 30 μmol/L of at least one TGF-β inhibitor,
0.1 μmol/L to 10 μmol/L of at least one BMP inhibitor,
0.5 μmol/L to 30 μmol/L of at least one p53 inhibitor,
0.2 μmol/L to 30 μmol/L of at least one Notch inhibitor and
0.05 μmol/L to 10 μmol/L of at least one RAR agonist,

wherein the GSK3 inhibitor comprises CHIR99021, the TGF-β inhibitor comprises SB431542, the p53 inhibitor comprises pifithrin, the PI3K inhibitor comprises LY294002, the Notch inhibitor comprises DAPT, the RAR agonist comprises retinoic acid, or the cAMP inducer comprises forskolin.

7. The composition according to claim 6 , comprising the GSK3 inhibitor, the TGF-β inhibitor, the p53 inhibitor, the Notch inhibitor, the RAR agonist, the PI3K inhibitor, and the cAMP inducer.

8. The composition according to claim 6 , wherein the composition comprises the BMP inhibitor, and the BMP inhibitor comprises LDN193189.

9. The process for producing an insulin-producing cell according to claim 1 , wherein the fibroblast is cultured in the presence of the TGF-β inhibitor, and the TGF-β inhibitor comprises SB431542.

10. The process for producing an insulin-producing cell according to claim 1 , wherein the fibroblast is cultured in the presence of the p53 inhibitor, and the p53 inhibitor comprises pifithrin.

11. The process for producing an insulin-producing cell according to claim 1 , wherein the fibroblast is cultured in the presence of the Notch inhibitor, and the Notch inhibitor comprises DAPT.

12. A process for producing an insulin-producing cell by inducing differentiation directly from a fibroblast without performing artificial gene transfer, the process comprising culturing the fibroblast in the presence of:
an effective amount of one or more cAMP inducers;
an effective amount of one or more PI3K inhibitors;
an effective amount of one or more GSK3 inhibitors;
an effective amount of one or more TGF-β inhibitors; and
an effective amount of one or more Notch inhibitors,
wherein the GSK3 inhibitor comprises CHIR99021, the TGF-β inhibitor comprises SB431542, the PI3K inhibitor comprises LY294002, the Notch inhibitor comprises DAPT, or the cAMP inducer comprises forskolin.

13. The process according to claim 12 , wherein the culturing further comprises culturing the fibroblast in the presence of an effective amount of one or more p53 inhibitors.

Assignees

• Kataoka Corp
• Kyoto Prefectural Public Univ Corp

Inventors

• Dai Ping
• Takeda Yukimasa
• Harada Yoshinori
• Matsumoto Junichi
• Kusaka Ayumi

Classifications

• C12N2506/1307

  from adult fibroblasts · CPC title

• C12N2501/999

  Small molecules not provided for elsewhere · CPC title

• A61L27/36

  containing ingredients of undetermined constitution or reaction products thereof {, e.g. transplant tissue, natural bone, extracellular matrix (isolated natural compounds, e.g. collagen A61L27/24)} · CPC title

• A61L27/38

  containing added animal cells (organs or tissue containing native cells A61L27/36) · CPC title

• A61K35/545

  Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells · CPC title